Robert Hynds, PhD, UCL, London, UK, discusses patient-derived xenograft models for preclinical oncology research. Whilst the majority of preclinical research relies on cancer cell lines or genetically engineered mouse models, patient derived xenograft models hold the advantage of being more representative of human tumors and are thus more reliable. https://www.biorxiv.org/content/10.1101/2023.01.06.521078v1.full. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.